Semaglutide
A+
87.5/100
Evidence Summary
Semaglutide is the highest-evidence longevity compound in the ClinEvident registry. Originally approved for type 2 diabetes (Ozempic) and obesity (Wegovy), it has demonstrated significant benefits across multiple organ systems in large randomized controlled trials.
The FLOW trial (NEJM 2024) showed a 24% reduction in composite kidney outcomes. The SELECT trial showed a 20% reduction in major cardiovascular events in non-diabetic adults with obesity. These are hard clinical endpoints from dedicated Phase 3 RCTs — the gold standard of evidence.
Critical safety note: GLP-1 therapy causes 30-40% lean mass loss alongside fat loss. Resistance training is a MANDATORY combination to prevent sarcopenia. Cold water immersion post-resistance training is directly counterproductive for GLP-1 patients.
The FLOW trial (NEJM 2024) showed a 24% reduction in composite kidney outcomes. The SELECT trial showed a 20% reduction in major cardiovascular events in non-diabetic adults with obesity. These are hard clinical endpoints from dedicated Phase 3 RCTs — the gold standard of evidence.
Critical safety note: GLP-1 therapy causes 30-40% lean mass loss alongside fat loss. Resistance training is a MANDATORY combination to prevent sarcopenia. Cold water immersion post-resistance training is directly counterproductive for GLP-1 patients.
Safety Considerations
30-40% of weight loss is lean mass without resistance exercise countermeasure. Resistance training is MANDATORY. GI side effects (nausea, vomiting) common in titration phase. Pancreatitis risk (rare). Contraindicated in personal/family history of medullary thyroid carcinoma or MEN2. Do not combine with cold water immersion post-resistance training.
Evidence Signals (0)
Known Interactions (1)
Products Containing Semaglutide
These are commercial products that contain this molecule. The grade above applies to the molecule as tested in published trials — it is not a grade of any product below. We show each product's actual dose next to the evidence dose so you can see the match or the gap.
Wegovy Novo Nordisk
2.4 mg
Ozempic Novo Nordisk
2 mg
Product information retrieved 5/28/2026. Formulations change without notice — verify on the label before use.
Regulatory Intelligence
This evidence profile reflects publicly available research as of March 15, 2026. Evidence grades may change as new research is published. ClinEvident grades the quality of published evidence — it does not evaluate the efficacy of any specific commercial product.